Bryn Mawr Capital Management LLC Sells 4,756 Shares of Becton, Dickinson and Company (NYSE:BDX)

Bryn Mawr Capital Management LLC lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 48.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,089 shares of the medical instruments supplier’s stock after selling 4,756 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $1,241,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Sapient Capital LLC bought a new position in Becton, Dickinson and Company during the fourth quarter valued at $1,295,000. Vest Financial LLC lifted its holdings in shares of Becton, Dickinson and Company by 27.5% in the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after acquiring an additional 22,207 shares during the last quarter. M. Kulyk & Associates LLC lifted its holdings in shares of Becton, Dickinson and Company by 5.1% in the 3rd quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock worth $4,302,000 after acquiring an additional 809 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock worth $3,685,000 after acquiring an additional 6,190 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.1% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 714,114 shares of the medical instruments supplier’s stock worth $174,122,000 after acquiring an additional 7,790 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of several analyst reports. Barclays raised their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Raymond James raised their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Trading Up 0.5 %

BDX stock opened at $231.55 on Friday. The company has a market capitalization of $66.89 billion, a PE ratio of 54.87, a P/E/G ratio of 1.90 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The firm’s 50-day moving average is $239.24 and its 200 day moving average is $241.42. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping the consensus estimate of $2.39 by $0.29. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.98 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.